|Awarded On||February 18, 2015|
|Title||Armada Pharmaceuticals Inc. New Company Formation for Development of Anti-Cancer Antibody-Drug Conjugate Therapeutics|
|Program||Product Development Research|
|Award Mechanism||New Company Product Development Award|
|Institution/Organization||Formation Biologics Corporation|
|Principal Investigator/Program Director||Ilia Tikhomirov|
|Cancer Sites||Breast, Head and Neck, Lung and Bronchus, Stomach|
Armada Pharmaceuticals Inc is developing an innovative pipeline of targeted anti-cancer therapeutics called antibody-drug conjugates (ADCs). These next-generation treatments can have superior safety and efficacy. Armada’s high-potential pipeline was developed using a cutting-edge platform integrating genomics, proteomics and bioinformatics technologies.
Armada’s lead product, AVID100, has been extensively studied in disease models, and demonstrated excellent safety and efficacy against many deadly cancers displaying the EGFR marker, including breast, ovarian, head and neck, glioma, pancreatic, gastric, and lung cancers. Compared to the FDA-approved anti-EGFR antibody Erbitux® (sales of ~$2 b...